CagriSema

What it is

A fixed-dose combination of two peptides co-administered in a single weekly subcutaneous injection, developed by Novo Nordisk. Cagrilintide is a 37-amino-acid long-acting acylated amylin analogue; semaglutide is a 31-amino-acid GLP-1 receptor agonist. The two components target complementary satiety pathways — amylin receptors in the area postrema/hindbrain and GLP-1 receptors in the hypothalamus/brainstem. Phase 3 data (REDEFINE 1) reported −22.7% on-treatment weight loss at 68 weeks. An NDA was filed with the FDA in December 2025.

Community-reported ranges

Clinical trial data from published Phase 1b/2/3 results. Combination is not available as a research peptide. Not dosing guidance.

Frequently discussed alongside

Based on community forum discussions. Not a recommendation to combine compounds.

Published research

Phase 1b (Enebo et al., Lancet 2021) showed cagrilintide 2.4 mg added to semaglutide 2.4 mg produced −17.1% total weight loss over 20 weeks. REDEFINE 1 (NEJM 2025; n=3,417) demonstrated −22.7% on-treatment weight loss at 68 weeks, with 23.1% achieving ≥30% loss. REDEFINE 2 (NEJM 2025; n=1,206) showed −15.7% weight loss in T2D with 73.5% reaching HbA1c ≤6.5%. REDEFINE 4 compared CagriSema head-to-head vs tirzepatide 15 mg; CagriSema achieved ~23% loss but did not demonstrate statistical superiority. Preclinical data suggest approximately one-third of CagriSema's weight loss effect is attributed to preserved energy expenditure. Clinical titration co-escalates both components every 4 weeks from 0.25/0.25 mg to 2.4/2.4 mg.

Reported side effects

From community self-reports. Not from controlled studies.

REDEFINE 1 reported GI adverse events in 79.6% of CagriSema recipients (vs 39.9% placebo), primarily nausea, vomiting, diarrhea, constipation, and abdominal pain — mostly transient and mild to moderate. Discontinuation due to adverse events was 5.9%. Anti-cagrilintide antibodies developed in 46–73% of Phase 2 monotherapy participants. Semaglutide class warnings include thyroid C-cell tumor risk (boxed warning), pancreatitis, and gallbladder disorders.

Regulatory status